Arvinas (ARVN) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

ARVN Stock Forecast

Arvinas stock forecast is as follows: an average price target of $71.82 (represents a 219.48% upside from ARVN’s last price of $22.48) and a rating consensus of 'Buy', based on 13 wall street analysts offering a 1-year stock forecast.

ARVN Price Target

The average price target for Arvinas (ARVN) is $71.82 based on 1-year price targets from 13 Wall Street analysts in the past 3 months, with a price target range of $123.00 to $24.00. This represents a potential 219.48% upside from ARVN's last price of $22.48.

ARVN Analyst Ratings

Buy

According to 13 Wall Street analysts, Arvinas's rating consensus is 'Buy'. The analyst rating breakdown for ARVN stock is 0 'Strong Buy' (0.00%), 11 'Buy' (84.62%), 2 'Hold' (15.38%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Arvinas Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Oct 31, 2024	Matthew Biegler	Oppenheimer	$40.00	$27.66	44.61%	77.94%
Oct 21, 2024	Bradley Canino	Stifel Nicolaus	$63.00	$27.11	132.39%	180.25%
May 16, 2024	Matthew Biegler	Oppenheimer	$70.00	$32.11	118.00%	211.39%
Apr 12, 2024	Andrew Fein	H.C. Wainwright	$87.00	$37.26	133.49%	287.01%
Apr 11, 2024	Bradley Canino	Stifel Nicolaus	$72.00	$38.73	85.90%	220.28%
Dec 19, 2023	Derek Archila	Wells Fargo	$63.00	$37.87	66.36%	180.25%
Oct 23, 2023	Robert Driscoll	Wedbush	$24.00	$14.83	61.83%	6.76%
Jan 03, 2023	-	Wells Fargo	$49.00	$34.21	43.23%	117.97%
Dec 05, 2022	-	Citigroup	$72.00	$41.39	73.96%	220.28%
Nov 23, 2022	-	Barclays	$70.00	$40.70	71.99%	211.39%

Row per page

Go to

The latest Arvinas stock forecast, released on Oct 31, 2024 by Matthew Biegler from Oppenheimer, set a price target of $40.00, which represents a 44.61% increase from the stock price at the time of the forecast ($27.66), and a 77.94% increase from ARVN last price ($22.48).

Arvinas Price Target by Period

	1M	3M	12M
# Anlaysts	2	2	6
Avg Price Target	$51.50	$51.50	$65.83
Last Closing Price	$22.48	$22.48	$22.48
Upside/Downside	129.09%	129.09%	192.84%

In the current month, the average price target of Arvinas stock is $51.50, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 129.09% increase as opposed to Arvinas's last price of $22.48. This month's average price target is down 0.00% compared to last quarter, and down -21.77% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 31, 2024	Oppenheimer	Outperform	Outperform	Hold
Sep 09, 2024	Wedbush	Buy	Buy	Hold
Jul 31, 2024	Wells Fargo	Buy	Buy	Hold
May 17, 2024	Wells Fargo	Buy	Buy	Hold
May 16, 2024	Oppenheimer	Outperform	Outperform	Hold
Apr 12, 2024	H.C. Wainwright	Buy	Buy	Hold
Dec 19, 2023	Wells Fargo	Equal-Weight	Overweight	Upgrade
Dec 06, 2023	Jefferies	-	Buy	Upgrade
Nov 20, 2023	Guggenheim	Neutral	Buy	Upgrade
Oct 24, 2023	Barclays	Overweight	Overweight	Hold

Row per page

Go to

Arvinas's last stock rating was published by Oppenheimer on Oct 31, 2024. The company gave ARVN a "Outperform" rating, the same as its previous rate.

Arvinas Financial Forecast

Arvinas Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Sep 18
Revenue	-	-	-	-	-	-	-	-	$-43.10M	$34.60M	$54.50M	$32.50M	$38.00M	$30.30M	$31.30M	$24.20M	$25.63M	$9.28M	$5.54M	$5.54M	$2.22M	$7.60M	$5.75M	$6.24M	$4.89M	$30.05M	$4.02M	$4.02M	$3.38M
Avg Forecast	$85.90M	$58.98M	$36.41M	$36.51M	$59.37M	$60.56M	$33.27M	$32.94M	$48.33M	$39.45M	$30.94M	$27.91M	$35.72M	$34.70M	$24.75M	$25.45M	$14.14M	$196.39M	$5.60M	$3.68M	$6.89M	$5.22M	$5.36M	$4.44M	$5.34M	$4.44M	$3.69M	$3.44M	$7.50M
High Forecast	$152.27M	$104.55M	$64.55M	$64.73M	$131.78M	$107.35M	$33.27M	$32.94M	$69.63M	$39.52M	$54.84M	$49.48M	$63.31M	$34.70M	$24.75M	$25.45M	$14.14M	$196.39M	$5.60M	$3.68M	$6.89M	$5.22M	$5.36M	$4.44M	$5.34M	$4.44M	$3.69M	$3.44M	$9.00M
Low Forecast	$54.60M	$37.49M	$23.15M	$23.21M	$32.73M	$38.49M	$33.27M	$32.94M	$37.27M	$39.39M	$19.67M	$17.74M	$22.70M	$34.70M	$24.75M	$25.45M	$14.14M	$196.39M	$5.60M	$3.68M	$6.89M	$5.22M	$5.36M	$4.44M	$5.34M	$4.44M	$3.69M	$3.44M	$6.00M
# Analysts	3	3	3	5	12	6	6	6	12	9	9	9	5	5	5	5	6	6	6	7	9	9	9	9	13	13	13	13	15
Surprise %	-	-	-	-	-	-	-	-	-0.89%	0.88%	1.76%	1.16%	1.06%	0.87%	1.26%	0.95%	1.81%	0.05%	0.99%	1.51%	0.32%	1.45%	1.07%	1.40%	0.92%	6.78%	1.09%	1.17%	0.45%

Arvinas's average Quarter revenue forecast for Mar 24 based on 6 analysts is $32.94M, with a low forecast of $32.94M, and a high forecast of $32.94M. ARVN's average Quarter revenue forecast represents a -176.43% decrease compared to the company's last Quarter revenue of $-43.10M (Dec 23).

Arvinas EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Sep 18
# Analysts	3	3	3	5	12	6	6	6	12	9	9	9	5	5	5	5	6	6	6	7	9	9	9	9	13	13	13	13	15
EBITDA	-	-	-	-	-	-	-	-	$-165.30M	$-73.90M	$-74.60M	$-87.70M	$-75.40M	$-65.10M	$-66.40M	$-57.90M	$-52.37M	$-45.23M	$-48.80M	$-39.49M	$-40.24M	$-29.71M	$-24.35M	$-20.94M	$-20.31M	$-17.04M	$-16.65M	$-13.95M	$-13.18M
Avg Forecast	$-85.90M	$-58.98M	$-36.41M	$-36.51M	$-59.37M	$-60.56M	$-33.27M	$-43.84M	$-48.33M	$-39.45M	$-30.94M	$-39.86M	$-35.95M	$-34.70M	$-24.75M	$-36.23M	$-14.14M	$-196.39M	$-5.60M	$-38.53M	$-6.89M	$-5.22M	$-5.36M	$-22.33M	$-5.34M	$-4.44M	$-3.69M	$-13.95M	$-29.31M
High Forecast	$-54.60M	$-37.49M	$-23.15M	$-23.21M	$-32.73M	$-38.49M	$-33.27M	$-35.07M	$-37.27M	$-39.39M	$-19.67M	$-31.89M	$-28.76M	$-34.70M	$-24.75M	$-28.99M	$-14.14M	$-196.39M	$-5.60M	$-30.83M	$-6.89M	$-5.22M	$-5.36M	$-17.86M	$-5.34M	$-4.44M	$-3.69M	$-11.16M	$-23.44M
Low Forecast	$-152.27M	$-104.55M	$-64.55M	$-64.73M	$-131.78M	$-107.35M	$-33.27M	$-52.61M	$-69.63M	$-39.52M	$-54.84M	$-47.83M	$-43.14M	$-34.70M	$-24.75M	$-43.48M	$-14.14M	$-196.39M	$-5.60M	$-46.24M	$-6.89M	$-5.22M	$-5.36M	$-26.80M	$-5.34M	$-4.44M	$-3.69M	$-16.75M	$-35.17M
Surprise %	-	-	-	-	-	-	-	-	3.42%	1.87%	2.41%	2.20%	2.10%	1.88%	2.68%	1.60%	3.70%	0.23%	8.72%	1.03%	5.84%	5.69%	4.55%	0.94%	3.80%	3.84%	4.51%	1.00%	0.45%

undefined analysts predict ARVN's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Arvinas's previous annual EBITDA (undefined) of $NaN.

Arvinas Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Sep 18
# Analysts	3	3	3	5	12	6	6	6	12	9	9	9	5	5	5	5	6	6	6	7	9	9	9	9	13	13	13	13	15
Net Income	-	-	-	-	-	-	-	-	$-154.80M	$-64.00M	$-66.60M	$-80.80M	$-79.90M	$-66.20M	$-70.00M	$-63.40M	$-53.06M	$-46.75M	$-50.29M	$-40.96M	$-41.55M	$-30.82M	$-25.23M	$-21.74M	$-21.05M	$-17.68M	$-17.16M	$-14.40M	$-13.39M
Avg Forecast	$-75.50M	$-76.16M	$-98.24M	$-92.83M	$-74.56M	$-60.76M	$-78.19M	$-49.99M	$-85.71M	$-114.12M	$-118.95M	$-45.45M	$-36.38M	$-83.72M	$-78.74M	$-41.32M	$-56.61M	$152.57M	$-62.05M	$-39.97M	$-54.49M	$-48.95M	$-42.65M	$-23.19M	$-38.94M	$-33.30M	$-28.87M	$-14.40M	$-29.76M
High Forecast	$-39.74M	$-40.08M	$-51.71M	$-64.11M	$-20.85M	$-31.98M	$-41.15M	$-39.99M	$-48.33M	$-60.07M	$-62.61M	$-36.36M	$-29.10M	$-83.72M	$-78.74M	$-33.05M	$-56.61M	$152.57M	$-62.05M	$-31.97M	$-54.49M	$-48.95M	$-42.65M	$-18.55M	$-38.94M	$-33.30M	$-28.87M	$-11.52M	$-23.81M
Low Forecast	$-151.33M	$-152.65M	$-196.91M	$-109.52M	$-118.15M	$-121.78M	$-156.72M	$-59.99M	$-128.25M	$-228.75M	$-238.44M	$-54.54M	$-43.65M	$-83.72M	$-78.74M	$-49.58M	$-56.61M	$152.57M	$-62.05M	$-47.96M	$-54.49M	$-48.95M	$-42.65M	$-27.83M	$-38.94M	$-33.30M	$-28.87M	$-17.29M	$-35.71M
Surprise %	-	-	-	-	-	-	-	-	1.81%	0.56%	0.56%	1.78%	2.20%	0.79%	0.89%	1.53%	0.94%	-0.31%	0.81%	1.03%	0.76%	0.63%	0.59%	0.94%	0.54%	0.53%	0.59%	1.00%	0.45%

Arvinas's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ARVN's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Arvinas SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Sep 18
# Analysts	3	3	3	5	12	6	6	6	12	9	9	9	5	5	5	5	6	6	6	7	9	9	9	9	13	13	13	13	15
SG&A	-	-	-	-	-	-	-	-	$27.00M	$22.60M	$25.70M	$24.90M	$15.10M	$20.00M	$24.30M	$20.20M	$18.26M	$16.01M	$14.41M	$12.32M	$12.23M	$9.33M	$8.82M	$7.93M	$7.27M	$7.96M	$6.44M	$5.64M	$4.28M
Avg Forecast	$96.12M	$66.00M	$40.75M	$40.86M	$66.43M	$67.76M	$37.23M	$15.93M	$54.08M	$44.15M	$34.62M	$14.48M	$12.53M	$38.24M	$27.27M	$13.16M	$15.58M	$216.40M	$6.17M	$4.06M	$7.59M	$5.75M	$5.90M	$4.90M	$5.89M	$4.89M	$4.06M	$3.79M	$8.27M
High Forecast	$170.38M	$116.99M	$72.23M	$72.43M	$147.46M	$120.12M	$37.23M	$19.11M	$77.91M	$44.22M	$61.37M	$17.38M	$15.04M	$38.24M	$27.27M	$15.80M	$15.58M	$216.40M	$6.17M	$4.06M	$7.59M	$5.75M	$5.90M	$4.90M	$5.89M	$4.89M	$4.06M	$3.79M	$9.92M
Low Forecast	$61.10M	$41.95M	$25.90M	$25.97M	$36.62M	$43.07M	$37.23M	$12.74M	$41.70M	$44.07M	$22.01M	$11.58M	$10.03M	$38.24M	$27.27M	$10.53M	$15.58M	$216.40M	$6.17M	$4.06M	$7.59M	$5.75M	$5.90M	$4.90M	$5.89M	$4.89M	$4.06M	$3.79M	$6.61M
Surprise %	-	-	-	-	-	-	-	-	0.50%	0.51%	0.74%	1.72%	1.20%	0.52%	0.89%	1.53%	1.17%	0.07%	2.34%	3.04%	1.61%	1.62%	1.49%	1.62%	1.23%	1.63%	1.59%	1.49%	0.52%

Arvinas's average Quarter SG&A projection for Mar 24 is $15.93M, based on 6 Wall Street analysts, with a range of $12.74M to $19.11M. The forecast indicates a -41.01% fall compared to ARVN last annual SG&A of $27.00M (Dec 23).

Arvinas EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Sep 18
# Analysts	3	3	3	5	12	6	6	6	12	9	9	9	5	5	5	5	6	6	6	7	9	9	9	9	13	13	13	13	15
EPS	-	-	-	-	-	-	-	-	$-2.53	$-1.18	$-1.25	$-1.52	$-1.50	$-1.24	$-1.32	$-1.20	$-1.00	$-0.94	$-1.03	$-0.84	$-0.99	$-0.79	$-0.65	$-0.56	$-0.56	$-0.54	$-0.55	$-0.46	$-6.66
Avg Forecast	$-1.05	$-1.06	$-1.36	$-1.29	$-1.03	$-0.84	$-1.08	$-1.42	$-1.19	$-1.58	$-1.65	$-1.54	$-1.17	$-1.16	$-1.10	$-0.93	$-0.79	$2.12	$-0.86	$-0.83	$-0.76	$-0.68	$-0.59	$-0.57	$-0.54	$-0.46	$-0.40	$-0.46	$-3.31
High Forecast	$-0.55	$-0.56	$-0.72	$-0.89	$-0.29	$-0.44	$-0.57	$-0.75	$-0.67	$-0.83	$-0.87	$-0.81	$-0.62	$-1.16	$-1.10	$-0.93	$-0.79	$2.12	$-0.86	$-0.83	$-0.76	$-0.68	$-0.59	$-0.57	$-0.54	$-0.46	$-0.40	$-0.46	$-2.65
Low Forecast	$-2.10	$-2.12	$-2.73	$-1.52	$-1.64	$-1.69	$-2.17	$-2.85	$-1.78	$-3.17	$-3.31	$-3.09	$-2.35	$-1.16	$-1.10	$-0.93	$-0.79	$2.12	$-0.86	$-0.83	$-0.76	$-0.68	$-0.59	$-0.57	$-0.54	$-0.46	$-0.40	$-0.46	$-3.97
Surprise %	-	-	-	-	-	-	-	-	2.13%	0.75%	0.76%	0.99%	1.28%	1.06%	1.21%	1.29%	1.27%	-0.44%	1.19%	1.01%	1.31%	1.16%	1.10%	0.99%	1.03%	1.17%	1.37%	0.99%	2.01%

According to undefined Wall Street analysts, Arvinas's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ARVN previous annual EPS of $NaN (undefined).

Arvinas Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
IPSC	Century Therapeutics	$1.22	$15.00	1129.51%	Buy
STTK	Shattuck Labs	$1.24	$12.00	867.74%	Hold
BDTX	Black Diamond Therapeutics	$2.62	$14.75	462.98%	Buy
RLAY	Relay Therapeutics	$5.11	$19.40	279.65%	Buy
ARVN	Arvinas	$22.48	$71.82	219.48%	Buy
PLRX	Pliant Therapeutics	$12.43	$39.71	219.47%	Buy
CCCC	C4 Therapeutics	$4.31	$13.50	213.23%	Buy
STOK	Stoke Therapeutics	$12.03	$30.60	154.36%	Buy
RARE	Ultragenyx Pharmaceutical	$44.75	$106.93	138.95%	Buy
FHTX	Foghorn Therapeutics	$8.01	$16.33	103.87%	Buy
KURA	Kura Oncology	$15.92	$26.00	63.32%	Buy
NRIX	Nurix Therapeutics	$22.92	$32.20	40.49%	Buy
CRNX	Crinetics Pharmaceuticals	$54.72	$70.14	28.18%	Buy
KYMR	Kymera Therapeutics	$41.96	$51.50	22.74%	Buy
RVMD	Revolution Medicines, Inc. Warrant	$55.13	$60.63	9.98%	Buy

ARVN Forecast FAQ

Is Arvinas a good buy?

Yes, according to 13 Wall Street analysts, Arvinas (ARVN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 11 'Buy' recommendations, accounting for 84.62% of ARVN's total ratings.

What is ARVN's price target?

Arvinas (ARVN) average price target is $71.82 with a range of $24 to $123, implying a 219.48% from its last price of $22.48. The data is based on 13 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Arvinas stock go up soon?

According to Wall Street analysts' prediction for ARVN stock, the company can go up by 219.48% (from the last price of $22.48 to the average price target of $71.82), up by 447.15% based on the highest stock price target, and up by 6.76% based on the lowest stock price target.

Can Arvinas stock reach $30?

ARVN's average twelve months analyst stock price target of $71.82 supports the claim that Arvinas can reach $30 in the near future.

What is Arvinas's current price target trend?

2 Wall Street analysts forecast a $51.5 price target for Arvinas (ARVN) this month, up 129.09% from its last price of $22.48. Compared to the last 3 and 12 months, the average price target increased by 129.09% and increased by 192.84%, respectively.

What are Arvinas's analysts' financial forecasts?

Arvinas's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $186.14M (high $305.35M, low $137.43M), average EBITDA is $-197M (high $-140M, low $-325M), average net income is $-263M (high $-134M, low $-457M), average SG&A $187.35M (high $323.92M, low $129.66M), and average EPS is $-4.381 (high $-2.051, low $-8.347). ARVN's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $217.81M (high $386.09M, low $138.45M), average EBITDA is $-218M (high $-138M, low $-386M), average net income is $-343M (high $-196M, low $-610M), average SG&A $243.72M (high $432.03M, low $154.92M), and average EPS is $-4.753 (high $-2.713, low $-8.466).

Did the ARVN's actual financial results beat the analysts' financial forecasts?

Based on Arvinas's last annual report (Dec 2023), the company's revenue was $78.5M, which missed the average analysts forecast of $146.64M by -46.47%. Apple's EBITDA was $-402M, beating the average prediction of $-159M by 153.18%. The company's net income was $-367M, beating the average estimation of $-364M by 0.84%. Apple's SG&A was $100.3M, missing the average forecast of $147.33M by -31.92%. Lastly, the company's EPS was $-6.62, beating the average prediction of $-5.961 by 11.05%. In terms of the last quarterly report (Dec 2023), Arvinas's revenue was $-43.1M, missing the average analysts' forecast of $48.33M by -189.17%. The company's EBITDA was $-165M, beating the average prediction of $-48.335M by 241.99%. Arvinas's net income was $-155M, beating the average estimation of $-85.712M by 80.61%. The company's SG&A was $27M, missing the average forecast of $54.08M by -50.08%. Lastly, the company's EPS was $-2.53, beating the average prediction of $-1.189 by 112.82%